IL301530A - The composition and method for preventing and treating skin radiation damage - Google Patents

The composition and method for preventing and treating skin radiation damage

Info

Publication number
IL301530A
IL301530A IL301530A IL30153023A IL301530A IL 301530 A IL301530 A IL 301530A IL 301530 A IL301530 A IL 301530A IL 30153023 A IL30153023 A IL 30153023A IL 301530 A IL301530 A IL 301530A
Authority
IL
Israel
Prior art keywords
composition
fiasma
radiation
cri
pharmaceutical composition
Prior art date
Application number
IL301530A
Other languages
English (en)
Hebrew (he)
Original Assignee
Rythera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rythera Therapeutics Inc filed Critical Rythera Therapeutics Inc
Publication of IL301530A publication Critical patent/IL301530A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL301530A 2020-09-22 2021-09-22 The composition and method for preventing and treating skin radiation damage IL301530A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063081718P 2020-09-22 2020-09-22
US202063081547P 2020-09-22 2020-09-22
PCT/US2021/051583 WO2022066791A1 (fr) 2020-09-22 2021-09-22 Compositions et méthodes de prévention et de traitement de lésion cutanée radique

Publications (1)

Publication Number Publication Date
IL301530A true IL301530A (en) 2023-05-01

Family

ID=80857195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301530A IL301530A (en) 2020-09-22 2021-09-22 The composition and method for preventing and treating skin radiation damage

Country Status (7)

Country Link
EP (1) EP4217001A4 (fr)
JP (1) JP7673210B2 (fr)
AU (2) AU2021349237B2 (fr)
CA (1) CA3193398A1 (fr)
IL (1) IL301530A (fr)
MX (1) MX2023003357A (fr)
WO (1) WO2022066791A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022351983A1 (en) * 2021-09-22 2024-04-18 Rythera Therapeutics Inc. Composition and method for prevention and treatment of cutaneous radiation injury
CN120091820A (zh) * 2022-09-22 2025-06-03 瑞特拉治疗公司 用于预防和治疗皮肤放射性损伤的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19621038A1 (de) * 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
ATE337003T1 (de) 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
US7250445B1 (en) * 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
PT2114896E (pt) * 2006-12-21 2015-11-04 Peter Maccallum Cancer Inst Compostos radio-protetores e métodos relacionados
US20090156982A1 (en) * 2007-09-06 2009-06-18 Arezou Petrie Transdermal treatment device and method
US9616006B2 (en) * 2007-10-10 2017-04-11 DermaMedics, LLC Methods and compositions for treating dermatological diseases and conditions
US20150353912A1 (en) * 2012-05-31 2015-12-10 Children's Hospital Medical Center Methods for treating and preventing radiation injury using activated protein c polypeptides
WO2016142341A1 (fr) 2015-03-06 2016-09-15 Repoceuticals Aps Mélatonine pour la prévention et le traitement de la vaginite et de la rectite radiques

Also Published As

Publication number Publication date
WO2022066791A1 (fr) 2022-03-31
AU2025202935A1 (en) 2025-05-15
MX2023003357A (es) 2023-06-30
AU2021349237A1 (en) 2023-06-08
AU2021349237B2 (en) 2025-05-01
JP7673210B2 (ja) 2025-05-14
JP2023544448A (ja) 2023-10-23
EP4217001A4 (fr) 2024-04-24
EP4217001A1 (fr) 2023-08-02
CA3193398A1 (fr) 2022-03-31

Similar Documents

Publication Publication Date Title
DK2600850T3 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6'-FLUORO- (N-METHYL OR N, N-DIMETHYL -) - 4-PHENYL-4 ', 9'-DIHYDRO-3'H-SPIRO [CYCLOHEXAN-1,1'-PYRANO [3,4, B] INDOL] -4-AMINE FOR TREATMENT OF NOCICEPTIVE PAIN
Fraser et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat
Ala et al. Topical diltiazem vs. topical glyceril trinitrate in the treatment of chronic anal fissure: a prospective, randomized, double-blind trial
IL301910A (en) Transcutaneous synthetic cannabidiol for the treatment of focal epilepsy in adults
AU2025202935A1 (en) Composition and method for prevention and treatment of cutaneous radiation injury
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
Ala et al. Effects of topical atorvastatin (2%) on posthemorrhoidectomy pain and wound healing: a randomized double-blind placebo-controlled clinical trial
US11179353B1 (en) Composition and method for prevention and treatment of radiation dermatitis
EP4405044A1 (fr) Compositions et méthodes de prévention et de traitement de lésion cutanée radique
US20240342114A1 (en) Compositon and method for prevention and treatment of cutaneous radiation injury
US20250241904A1 (en) Composition and method for prevention and treatment of cutaneous radiation injury
CN118317792A (zh) 用于预防和治疗皮肤放射性损伤的组合物和方法
HK40113806A (zh) 用於预防和治疗皮肤放射性损伤的组合物和方法
IL294170A (en) Topical cyclosporine for treating psoriasis and other ailments
US20240226024A1 (en) Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarbose
Webster Rosacea: A Review CME
EA046180B1 (ru) Фармацевтический состав флороглюцинола и триметилфлороглюцинола